Valneva SE

Executive Summary

Valneva SE is a French specialty vaccine company with a unique position as the developer of the world's only licensed chikungunya vaccine (Ixchiq) and a commercial cholera vaccine. The company's integrated model spans R&D through manufacturing, with facilities in Europe and the U.S. Its pipeline includes 46 drug candidates, notably the Lyme disease vaccine VLA15 (partnered with Pfizer) which is in Phase 3, and a new chikungunya vaccine trial (VLA1553) in pre-clinical stage for pediatric indications. Valneva's commercial portfolio provides near-term revenue, while its late-stage pipeline offers significant upside, albeit with execution risk. Financially, Valneva is publicly traded with a market cap of ~$530 million (estimated). The company has conducted three funding rounds and maintains operations across Europe and North America. Key upcoming events include the Phase 3 data readout for VLA15 and potential regulatory expansions for Ixchiq. While Valneva faces competition and regulatory hurdles, its expertise in vaccines and established products provide a foundation for growth. The upcoming catalysts could drive significant value if successful, balanced by the inherent risks of drug development.

Upcoming Catalysts (preview)

• H2 2026Lyme disease vaccine (VLA15) Phase 3 data readout70% success
• Q3 2026Chikungunya vaccine (Ixchiq) EU marketing authorization80% success